Evaluating Patient Screening for LY3954068, an Anti-Tau siRNA Protein Therapy, in Symptomatic Early Onset Alzheimer's Disease (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR127.10 / T32; Pres time: Nov 16, 2026; 08:00 AM - 12:00 PM; Location: WCC Halls A-C; "The correlation of tau and cognitive decline links tau accumulation to neurodegeneration. The IP is expected to reduce measurable tau levels and improve patient impressions on F18 tau PETs and in other secondary endpoints. The most common exclusion reason involved medications, ATTs, and exclusionary criteria like dementias, neuropsychiatric diseases, and more."
Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Mental Retardation • CD9 • MAPT
|